New Case Western Reserve research identifies local hotspots and links environmental factors like extreme heat to increased ...

Emerging clinical and autopsy evidence points to late-onset epilepsy as a potentially distinct, neurodegeneration-related ...

Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...

Please provide your email address to receive an email when new articles are posted on . Focal cortex stimulation with an implantable device reduced seizure activity in more than 50% of participants at ...

GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...

Where you grow old in the United States may change your odds of developing epilepsy. A new study in JAMA Neurology has mapped where older Americans are most likely to be diagnosed with epilepsy and ...

One of the most common causes of epilepsy is a structural brain abnormality. “Epilepsy can result from structural issues in ...

GLP-1s are linked to lower seizure recurrence, hospitalization, and mortality risk than other glucose-lowering drugs in adults with epilepsy, new research shows.

Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy ...

Moving forward The CDC reports that one in 100 U.S. adults has active epilepsy, and studies suggest that one third of these are not receiving adequate treatment or care. 30 Although this recent report ...